Prolonged use of intravenous isoniazid and rifampin.
We present a case of a 55-year-old woman requiring prolonged therapy with intravenous isoniazid and rifampin secondary to extensive bowel disease. We believe that this is the first U.S. report of a patient receiving both medications by the iv route. After months of therapy the patient has not experienced side effects secondary to this route of administration. We believe that iv isoniazid and rifampin provides a safe alternative method of delivery when clinical situations dictate this route.
Koestner
J A
JA
Department of Pharmaceutical Services, Vanderbilt University Hospital, Nashville, TN 37232.
Jones
L K
LK
Polk
W H
WH
Sawyers
J L
JL
D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007538:Isoniazid / Q000008:administration & dosage*; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage*; D014391:Tuberculosis, Miliary / Q000188:drug therapy*
D007538:Isoniazid; D012293:Rifampin